The efficacy of other biological agents, such as anakinra (IL1 inhibitor),29 abatacept (selective costimulation inhibitor),15 RTX (B-cell depleting antibodies)24 or tocilizumab (IL6 signalling inhibitor)13 has been confirmed in large placebo-controlled RCTs in patients with RA with inadequate response to aTNFs. The gene discussed is IL6; the disease is rheumatoid arthritis.